BioSpace News Archive

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended September 30, 2023.

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced its financial results for the third quarter ended September 30, 2023.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, announced that it has acquired Electronic Registry Systems, Inc., a market leader in cancer registry software and services.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended September 30, 2023, and provided a business update.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 36,800 shares of Astria’s common stock on November 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its third-quarter 2023 financial results.